Cara Therapeutics: A Look At The Next Catalyst—Osteoarthritis

Cara Therapeutics (NASDAQ:CARA) has been having a terrific 2017.Shares are up nearly 85% since the start of the year and the company recently released positive data for CR845 in uremic pruritus. Furthermore, the announcement of positive data allowed the company to raise money at a favorable valuation. I wrote an article back in January stating that I thought that the uremic pruritus data would be positive and that I would be holding through the UP-data release: "Cara Therapeutics represents one of my largest small capitalization biotech stock holdings and I will be holding through the uremic pruritus data release".

Back to news